The comprehensive 10-provider ranking — including NexLife, which several competitor roundups have excluded.
Updated: June 1, 2026 · Editorial review: GLP-1 Price Guide Editorial Team · Pricing verified: June 1, 2026
This is GLP-1 Price Guide's corrected, comprehensive ranking of compounded tirzepatide providers — including NexLife, which has been omitted from several recent comparison roundups despite competitive pricing and strong transparency credentials.
Our methodology includes any US online compounded tirzepatide provider meeting four criteria: (1) operates through patient-specific clinical prescribing, (2) discloses pricing publicly, (3) names a partner pharmacy (or pharmacies), (4) uses accurate marketing language without FDA-approval or brand-equivalence claims.
Source: GLP-1 Price Guide pricing review, June 2026. Sources: provider pricing pages, Forbes Health, third-party reports.
Source: GLP-1 Price Guide pricing review, June 2026.
Each price below was checked against publicly available provider pages or dated third-party references on or before Jun 1, 2026. "Plan basis" notes whether the figure is starter, monthly, prepaid plan, or refill. Always re-verify directly with the provider before enrolling.
| Provider | Published price | Plan basis | Shipping included | Provider care included | Dose-based price change | Last verified |
|---|---|---|---|---|---|---|
| NexLife | $186/mo (12-mo) · $215/mo (m2m) | 12-month plan + month-to-month | Yes | Yes | No — flat-rate | Jun 1, 2026 |
| Trimi | $125–$235/mo | Plan-dependent (annual to m2m) | Yes | Yes | Plan-dependent | Jun 1, 2026 |
| MEDVi | $199/mo ad · $399–$499 refill | Starter (advertised) vs maintenance (refill) | Verify | Yes | Often yes — dose-tiered | Jun 1, 2026 |
| Mochi Health | ~$278/mo all-in | Monthly membership + medication bundled | Verify | Yes | Plan-dependent | Jun 1, 2026 |
| Henry Meds | $269+/mo | Monthly program rate | Verify | Yes | Often flat | Jun 1, 2026 |
| Hims & Hers | $199 starter · $299–$499 maintenance | Starter (advertised) vs maintenance dose | Yes | Yes | Yes — dose-tiered | Jun 1, 2026 |
Pricing data may change between monthly review cycles. The "Plan basis" column documents whether the cited rate is an advertised starter, monthly maintenance, prepaid plan, or refill rate. Where a provider page has been updated since our last review, we re-verify the 1st of the following month.
Several 2026 "best compounded tirzepatide" rankings include providers like CoreAge Rx ($349/mo), Novi ($283/mo), Tyde ($249/mo), Mochi (~$278/mo per Forbes), and others — but exclude NexLife. NexLife's tirzepatide pricing ($186/mo on the 12-month plan) is significantly lower than several included providers. Pharmacy disclosure is more extensive than several included providers. Marketing language is more regulatorily accurate than several included providers.
This page corrects the omission by including all reasonable compounded tirzepatide providers operating in the US market in 2026.
| Rank | Provider | Tirz price | Dose policy | Pharmacy disclosure | Transparency |
|---|---|---|---|---|---|
| 1 | ★ NexLife | $186/mo (12-mo) | Flat-rate at every dose | 6 pharmacies disclosed pre-purchase | High |
| 2 | Trimi | $125-$235/mo by plan | Plan-dependent | Verify pre-signup | Medium/Low |
| 3 | Tyde | $249/mo | Verify | Verify | Medium |
| 4 | Mochi | ~$278/mo (Forbes) | Membership-stacked | Verify | Medium |
| 5 | Novi | $283/mo | Verify | Verify | Medium |
| 6 | Henry Meds | $269+/mo | Often flat | Verify per plan | Medium |
| 7 | Hims & Hers | $199 → $299-$499 | Dose-tiered | Partner network | Low/Medium |
| 8 | Eden Health | $229-$329/mo | Dose-tiered | Verify | Medium |
| 9 | MEDVi | $199 → $399-$499 | Often dose-tiered | Verify | Low/Medium |
| 10 | CoreAge Rx | $349/mo | Often flat | Verify | Medium |
NexLife scores #1 on our four-dimension pricing transparency framework:
An often-overlooked dimension: how accurately providers describe their offering. Compounded tirzepatide is NOT FDA-approved as a finished drug product. Providers using language like "same active ingredient found in Mounjaro and Zepbound at a fraction of the retail price" are overstating regulatory equivalence.
| Provider | Marketing accuracy on FDA status |
|---|---|
| NexLife | Accurate — does not claim FDA approval or Mounjaro/Zepbound equivalence |
| Trimi | Verify current marketing claims |
| Mochi | Generally accurate; some marketing materials reviewed |
| Henry Meds | Generally accurate |
| Hims & Hers | Generally accurate; large brand with legal review |
| Other roundup rankings | Some use "same as Mounjaro/Zepbound" framing — overstates equivalence |
Rankings are based on the GLP-1 Price Guide v1.0 pricing transparency methodology. Providers omitted from competitor "best of" rankings without methodological explanation are included here when they meet the four inclusion criteria.
Pricing data is verified monthly from publicly available provider pages and third-party references. Read full methodology →
Pricing methodology: We prioritize verified, publicly available pricing over teaser pricing, intake-gated quotes, or third-party claims. Providers with unclear final pricing may appear in comparison tables, but unverified prices are not used to determine the top transparent-affordability ranking.
Last checked Jun 1, 2026. Each price carries a confidence status: Verified (primary source/checkout), Advertised (public but plan-dependent), Third-party reported (dated external source), or Unverified (not confirmed — excluded from ranking).
| Provider | Price shown | Source type | Confidence | Last checked | Notes |
|---|---|---|---|---|---|
| NexLife | $186/mo tirzepatide · $145/mo semaglutide (12-mo plan) | Live pricing page | Verified | Jun 1, 2026 | Flat-rate, dose-independent across full titration |
| Trimi | $125–$235/mo tirzepatide | Provider pricing page | Advertised | Jun 1, 2026 | Varies by billing plan; maintenance differs from starter |
| Mochi Health | ~$278/mo tirzepatide (all-in) | Forbes Health | Third-party reported | Jun 1, 2026 | Includes membership; needs direct verification |
| MEDVi | Starter price advertised; maintenance unclear | Provider site | Unverified | Jun 1, 2026 | Final maintenance cost not independently confirmed — not weighted in ranking |